Synergistic Gene Expression System for Rod Photoreceptors
Legal Citation
Summary of the Inventive Concept
The inventive concept integrates SYNP161 promoter technology with cutting-edge technologies like AI, IoT, blockchain, and synthetic biology to create a powerful system for gene expression in rod photoreceptors, enabling advanced therapeutic and diagnostic applications.
Background and Problem Solved
The original patent SYNP161 promoter technology has limitations in terms of data tracking, analysis, and delivery of therapeutic proteins. The new inventive concept addresses these limitations by synergistically combining the promoter technology with distinct technologies to create a more powerful system for gene expression in rod photoreceptors.
Detailed Description of the Inventive Concept
The inventive concept consists of a nucleic acid molecule with at least 95% identity to SEQ ID NO:1, operatively linked to a gene encoding a therapeutic protein. The system incorporates a blockchain-based data storage system for tracking gene expression profiles, enabling secure and transparent data management. Additionally, the system may utilize artificial intelligence and machine learning algorithms to analyze gene expression data and predict optimal treatment strategies. The composition of matter may include a nanostructured material for enhanced delivery of the therapeutic protein to rod photoreceptors. Furthermore, the system may be integrated with IoT-enabled sensors for real-time tracking of gene expression levels, allowing for remote monitoring and personalized treatment. The inventive concept also encompasses the use of synthetic biology to design nucleic acid molecules with improved gene expression capabilities.
Novelty and Inventive Step
The new claims introduce novel and non-obvious combinations of technologies, including the integration of blockchain, AI, IoT, and synthetic biology with the SYNP161 promoter technology. These synergistic combinations provide a significant inventive step over the original patent, enabling advanced therapeutic and diagnostic applications.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept may include the use of different blockchain platforms, AI algorithms, or IoT sensor networks. Variations of the composition of matter may include different nanostructured materials or therapeutic proteins. The inventive concept may also be adapted for use in other cell types or tissues, expanding its potential applications.
Potential Commercial Applications and Market
The synergistic gene expression system has significant commercial potential in the fields of gene therapy, regenerative medicine, and precision medicine. The system's ability to track gene expression profiles, predict optimal treatment strategies, and enable remote monitoring makes it an attractive solution for pharmaceutical and biotechnology companies. The market for gene therapy and regenerative medicine is expected to grow significantly in the coming years, providing a substantial opportunity for the inventive concept.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K48/0058 |
| A | A61 | A61K48/00 |
| C | C12 | C12N15/63 |
| C | C12 | C12N15/79 |
| C | C12 | C12N15/86 |
| C | C12 | C12N2750/14143 |
| C | C12 | C12N2830/008 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Molecular biology, genetic engineering, and gene expression systems, specifically focused on promoter technologies for targeted cellular expression, with expertise in nucleic acid manipulation, vector design, and therapeutic gene delivery
Person of Ordinary Skill (PHOSITA) Profile
A molecular biologist or genetic engineer with advanced degree, proficient in sequence analysis, gene expression techniques, promoter characterization, and biotechnology integration techniques, familiar with emerging technologies like AI, blockchain, and synthetic biology
Obviousness Rationale
A PHOSITA would recognize that integrating emerging computational and biotechnology platforms with established gene expression technologies represents a predictable extension of known techniques. The core SYNP161 promoter technology provides a foundational platform that can be readily augmented with complementary technologies for enhanced functionality and data management. The proposed variations represent logical combinations of known techniques that would be apparent to a skilled practitioner seeking to optimize gene expression systems.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,642 |
|---|---|
| Title | SYNP161, a promoter for the expression of genes |
| Assignee(s) | FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH |